Added to YB: 2026-02-16
Pitch date: 2025-12-04
DERM [bullish]
Journey Medical Corporation
+7.22%
current return
Author Info
No bio for this author
Company Info
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
Market Cap
$265.7M
Pitch Price
$7.89
Price Target
N/A
Dividend
N/A
EV/EBITDA
-219.17
P/E
-21.26
EV/Sales
4.48
Sector
Pharmaceuticals
Category
growth
Journey Medical Corporation - $DERM
DERM: Emrosi launched April 2025, first oral rosacea drug in 20yrs showing superiority vs Oracea ($311M sales) in Phase 3: 62.7% vs 39% IGA success, 19 vs 14.8 lesion reduction. Base $55M rev business break-even. Mgmt targets $200M+ US peak sales, patents to 2039. Early traction: 34K scripts, 2,720 prescribers by Oct'25. Risk: execution, generics from 2027, payer dynamics.
Read full article (12 min)